These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 16575467)

  • 21. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure.
    Boige V; Malka D; Elias D; Castaing M; De Baere T; Goere D; Dromain C; Pocard M; Ducreux M
    Ann Surg Oncol; 2008 Jan; 15(1):219-26. PubMed ID: 17896145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I dose-escalating study of S-1 in combination with oxaliplatin for patients with advanced and/or metastatic colorectal cancer.
    Li J; Yin J; Zhu X; Liu Y; Cao J; Lu F; Zuo Y
    Anticancer Drugs; 2008 Aug; 19(7):745-8. PubMed ID: 18594218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multiple-center phase II study of biweekly oxaliplatin and tegafur-uracil/leucovorin for chemonaive patients with advanced gastric cancer.
    Chen JS; Rau KM; Chen YY; Huang JS; Yang TS; Lin YC; Liau CT; Lee KD; Su YC; Kao RH
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):819-25. PubMed ID: 18663448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study.
    Figer A; Perez-Staub N; Carola E; Tournigand C; Lledo G; Flesch M; Barcelo R; Cervantes A; André T; Colin P; Louvet C; de Gramont A
    Cancer; 2007 Dec; 110(12):2666-71. PubMed ID: 17963264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of modified FOLFOX6 for treatment of metastatic or locally advanced colorectal cancer. A single-institution outcome study.
    Matsumoto S; Nishimura T; Kanai M; Mori Y; Nagayama S; Kawamura J; Nomura A; Miyamoto S; Kitano T; Ishiguro H; Yanagihara K; Teramukai S; Sakai Y; Chiba T; Fukushima M
    Chemotherapy; 2008; 54(5):395-403. PubMed ID: 18781065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemoradiation with raltitrexed and oxaliplatin in preoperative treatment of stage II-III resectable rectal cancer: Phase I and II studies.
    Gambacorta MA; Valentini V; Coco C; Morganti AG; Smaniotto D; Miccichè F; Mantini G; Barbaro B; Garcia-Vargas JE; Magistrelli P; Picciocchi A; Cellini N
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):139-48. PubMed ID: 15337549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients.
    Seitz JF; Bennouna J; Paillot B; Gamelin E; François E; Conroy T; Raoul JL; Becouarn Y; Bertheault-Cvitkovic F; Ychou M; Nasca S; Fandi A; Barthelemy P; Douillard JY
    Ann Oncol; 2002 Jul; 13(7):1072-9. PubMed ID: 12176786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD).
    Cascinu S; Graziano F; Ferraù F; Catalano V; Massacesi C; Santini D; Silva RR; Barni S; Zaniboni A; Battelli N; Siena S; Giordani P; Mari D; Baldelli AM; Antognoli S; Maisano R; Priolo D; Pessi MA; Tonini G; Rota S; Labianca R
    Ann Oncol; 2002 May; 13(5):716-20. PubMed ID: 12075739
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer.
    Scheithauer W; Kornek GV; Raderer M; Ulrich-Pur H; Fiebiger W; Gedlicka C; Schüll B; Brugger S; Schneeweiss B; Lang F; Lenauer A; Depisch D
    J Clin Oncol; 2002 Jan; 20(1):165-72. PubMed ID: 11773166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oxaliplatin plus raltitrexed in the treatment of patients with advanced colorectal cancer: a phase II study.
    Martoni A; Mini E; Pinto C; Gentile AL; Nobili S; Dentico P; Marino A; Scicolone S; Angelelli B; Mazzei T
    Anticancer Res; 2003; 23(1B):687-91. PubMed ID: 12680168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Raltitrexed plus weekly oxaliplatin as first-line chemotherapy in metastatic colorectal cancer: a multicenter non-randomized phase ii study.
    Santini D; Massacesi C; D'Angelillo RM; Marcucci F; Campisi C; Vincenzi B; Pilone A; Bianco V; Bonsignori M; Tonini G
    Med Oncol; 2004; 21(1):59-66. PubMed ID: 15034215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy.
    Scheithauer W; Kornek GV; Schuell B; Ulrich-Pur H; Penz M; Raderer M; Lang F; Schneeweiss B; Lenauer A; Depisch D
    Ann Oncol; 2001 May; 12(5):709-14. PubMed ID: 11432632
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancement of the efficacy of chemotherapy with oxaliplatin plus 5-fluorouracil by pretreatment with IL-2 subcutaneous immunotherapy in metastatic colorectal cancer patients with lymphocytopenia prior to therapy.
    Lissoni P; Brivio F; Fumagalli L; Di Fede G; Brera G
    In Vivo; 2005; 19(6):1077-80. PubMed ID: 16277025
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Second-Line Treatment of Advanced Colorectal Cancer with a Biweekly Oxaliplatin plus Irinotecan Combination Regimen.
    Schüll B; Kornek GV; Schmid K; Raderer M; Ulrich-Pur H; Fiebiger W; Schneeweiss B; Lenauer A; Depisch D; Scheithauer W
    Onkologie; 2002 Aug; 25(4):358-62. PubMed ID: 12232488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Short-term effects of chemotherapy combined with hydroxycamptothecine and oxaliplatin in treatment of recurrent and metastatic colorectal cancer].
    Yao Y; Sun YJ; Zhao H; Guo YW; Lin F; Cai X; Tang XC
    Ai Zheng; 2006 Aug; 25(8):1035-8. PubMed ID: 16965689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tolerability of Raltitrexed ('Tomudex') in elderly patients with colorectal cancer.
    Romiti A; Tonini G; Santini D; Di Seri M; Masciangelo R; Mezi S; Verì A; Santuari L; Vincenzi B; Brescia A; Marchei P; Frati L; Tomao S
    Anticancer Res; 2002; 22(5):3071-6. PubMed ID: 12530045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Raltitrexed plus oxaliplatin in the treatment of metastatic colorectal cancer.
    Cortinovis D; Bajetta E; Di Bartolomeo M; Dognini G; Beretta E; Ferrario E; Ricotta R; Buzzoni R
    Tumori; 2004; 90(2):186-91. PubMed ID: 15237580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma: results of a Phase I-II trial.
    Scheithauer W; Kornek GV; Ulrich-Pur H; Penz M; Raderer M; Salek T; Haider K; Kwasny W; Depisch D
    Cancer; 2001 Apr; 91(7):1264-71. PubMed ID: 11283925
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer.
    Feliu J; Castañón C; Salud A; Mel JR; Escudero P; Pelegrín A; López-Gómez L; Ruiz M; González E; Juárez F; Lizón J; Castro J; González-Barón M;
    Br J Cancer; 2005 Nov; 93(11):1230-5. PubMed ID: 16265344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed.
    Schmid KE; Kornek GV; Schüll B; Raderer M; Lenauer A; Depisch D; Lang F; Scheithauer W
    Onkologie; 2003 Jun; 26(3):255-8. PubMed ID: 12845210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.